Download PDF
Drug Res (Stuttg) 2014; 64(5): 246-250
DOI: 10.1055/s-0033-1357178
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Atorvastatin Reduces the Myocardial Content of Coenzyme Q10 in Isoproterenol-induced Heart Failure in Rats

S. Andalib
1   Department of Pharmacology & Toxicology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
,
A. Shayanfar
2   Department of Medical Chemistry, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
,
A. Khorrami
1   Department of Pharmacology & Toxicology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
,
N. Maleki-Dijazi
1   Department of Pharmacology & Toxicology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
,
A. Garjani
1   Department of Pharmacology & Toxicology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
› Author Affiliations
Further Information

Publication History

received 26 June 2013

accepted 12 September 2013

Publication Date:
23 October 2013 (online)

Also available at
    Permissions and Reprints

Abstract

The present study was aimed to study the effects of different doses of atorvastatin on Co Q10 content in the myocardium tissue in rats. A subcutaneous injection of isoproterenol (5 mg/kg/day) for 10 days was used for the induction of heart failure. Rats were randomly assigned to control, treatment with atorvastatin (5, 10, 20 mg/kg/day) and treatment with atorvastatin plus coenzyme Q10 (10 mg/kg/day). Coenzyme Q10 content of myocardium was measured using HPLC method with UV detector after hemodynamic parameters measurements. The malondialdehyde (MDA) content of the myocardium was evaluated in order to determine coenzyme Q10 antioxidative effect. A high dose of atorvastatin (20 mg/kg/day) was significantly reduced the myocardium content of coenzyme Q10 as compared with isoproterenol treated group (p<0.001). Compared with atorvastatin alone treated animals, co-administration of coenzyme Q10 with atorvastatin was improved the level of coenzyme Q10 in the myocardium (p<0.05, p<0.001). Increasing the dose of atorvastatin also led to increase in MDA content of the myocardium (p<0.01). Serum lipid profile showed no changes in atorvastatin treated groups. The results of this study demonstrate that high doses of atorvastatin reduce coenzyme Q10 content of the myocardium and increase lipid peroxidation in myocardium which is reversed by coenzyme Q10 co-administration.

Key words

atorvastatin - heart failure - coenzyme Q10 - malondialdehyde
 

  • References

  • 1 Tamara B, Horwich M. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004; 43: 642-648
    CrossrefPubMedGoogle Scholar
  • 2 Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome. J Diabetes 2000; 14: 96-107
    PubMedGoogle Scholar
  • 3 van der Harst P, Voors AA, van Gilst WH et al. Statins in the treatment of chronic heart failure: a systematic review. PLoS Med 2006; 3: 333-337
    CrossrefPubMedGoogle Scholar
  • 4 Hayashidani S, Tsutsui H, Shiomi T. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 105: 868-873
    CrossrefPubMedGoogle Scholar
  • 5 Glynn RJ. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol 2006; 59: 819-828
    CrossrefPubMedGoogle Scholar
  • 6 Strandberg TE. Lipid-lowering drugs and heart failure: where do we go after the statin trials?. Curr Opin Cardiol 2010; 25: 385-393
    CrossrefPubMedGoogle Scholar
  • 7 van der Harst P, Böhm M, Wiek H et al. The case for statin therapy in chronic heart failure. Clinical Research in Cardiology 2008; 97: 139-146
    CrossrefPubMedGoogle Scholar
  • 8 Hiroshi M, Atsushi N, Kobayashi J et al. Effects of Co Q10 supplementation on plasma lipoprotein lipid, Co Q10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: A randomized double-blind study. Atherosclerosis 2007; 195: 182-189
    CrossrefPubMedGoogle Scholar
  • 9 James J, Nawarskas S. HMG-CoA Reductase Inhibitors and Coenzyme Q10. Cardiology in Review 2005; 13: 76-79
    CrossrefPubMedGoogle Scholar
  • 10 Alleva R, Tomasetti M, Bompadre S et al. Oxidation of LDL and their subfractions: kinetic aspects and Co Q10 content. J Mol Aspects Med 1997; 18: 105-112
    PubMedGoogle Scholar
  • 11 Schaars CF, Stalenhoef AF. Effects of ubiquinone (coenzyme Q10) on myopathy in statin users. Curr Opin Lipidol 2008; 19: 553-557
    CrossrefPubMedGoogle Scholar
  • 12 Ojha S, Goyal S, Kumari S et al. Pyruvate attenuates cardiac dysfunction and oxidative stress in isoproterenol-induced cardiotoxicity. Exp Toxicol Pathol 2012; 64: 393-399
    CrossrefPubMedGoogle Scholar
  • 13 Garjani A, Wainwright CL, Zeitlin IJ et al. Effects of endothelin-1 and the ETA-receptor antagonist, BQ123, on ischaemic arrhythmias in anaesthetized rats. J Cardiovas Pharmacol 1995; 25: 634-642
    CrossrefPubMedGoogle Scholar
  • 14 Kim SY, Lee E, Kim HP et al. A novel cerebroside from lycii fructus preserves the hepatic glutathione redox system in primary cultures of rat hepatocytes. Biological and Pharmaceutical Bulletin 1999; 22: 873-875
    CrossrefPubMedGoogle Scholar
  • 15 Willis RA, Folkers K, Tucker JL et al. Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci 1990; 87: 8928-8930
    CrossrefPubMedGoogle Scholar
  • 16 Satoh K, Yamato A, Nakai T et al. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischemic dog hearts. Br J Pharmacol 1995; 116: 1894-1898
    CrossrefPubMedGoogle Scholar
  • 17 Pepe S, Marasco SF, Haas SJ et al. Coenzyme Q10 in cardiovascular disease. J Mitochondrian 2007; 7: 154-167
    PubMedGoogle Scholar